- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04276727
Menthol In Neuropathy Trial (MINT)
A Phase II RCT of Topical Menthol Gel Versus Placebo in the Treatment of Chemotherapy Induced Peripheral Neuropathic Pain
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Modern cancer treatments, while more effective at prolonging life, are associated with some long lasting effects, especially nerve pain. This occurs in up to 90% of patients and 50% of patients still experience nerve pain a year after treatment. Not only is this distressing in itself but the investigators now understand that this treatment-related pain is exacerbating other pains, making cancer pain more difficult to control. The problem with managing nerve pain caused by treatment is that there is no predictable and effective treatment.
Our team has discovered that menthol cream or gel applied to the skin in the area of nerve pain can be effective. This trial seeks to provide better evidence of using this simple, cheap, non-toxic treatment. Participants will be given either menthol gel to the affected area or a placebo gel which smells, looks like and has the same texture as menthol but has no active drug. The gel will be applied twice a day for 6 weeks.
Participants will initially be assessed for pain and its impact on function, mood and quality of life and, if possible, will also have an fMRI scan immediately before starting menthol treatment and after 6 weeks of treatment. They will also have some assessments a further 6 weeks after treatment finishes. As part of impact on function assessment, participants will be asked to wear a physical activity monitor for a few days prior to each of the three main assessment points.
Our group has used special scans of the brain called fMRI to help identify if a treatment has real potential for patients. Sometimes, in early studies of a new treatment, patients can believe that the treatment has a real effect, but in fact it is a placebo effect. FMRI scans in this study will help to identify if menthol gel is having a true pain relieving effect, by comparing the patient's reports of pain with their scan findings. This will be very helpful in aiding the decision of how the research team conduct any future larger clinical trial.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Edinburgh, United Kingdom, EH4 2XU
- Western General Hospital
-
Edinburgh, United Kingdom, EH4 2XR
- Western General Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients have received any neurotoxic chemotherapy.
- Patients have experienced post treatment Chemotherapy Induced Peripheral Neuropathy (CIPN) pain for a minimum of 3 months after completing chemotherapy.
- Patients reporting a distressing or uncomfortable neuropathic symptom (such as pain or tingling) with an average score in the last 24 hours of ≥5 on a scale of 0-10 with 0 being none, according to the Numeric Rating Scale for pain.
- Aged 18 years or over at study entry.
- Patient's Oncology team agrees to their taking part in the study.
- Patients are able to provide written informed consent to participation in the study after explanation of the study protocol.
- In the opinion of the investigator, the patient is able to complete the various assessments.
- Neuropathy must be confined to the distal extremities (distal to elbows and/or knees).
Exclusion Criteria:
- Pre-existing or history of peripheral neuropathy due to any cause other than chemotherapy (diabetes, alcohol, toxin, hereditary, etc.).
- Patients with any contraindication to the use of topical therapy or menthol.
- Neurological conditions which may influence findings (such as Multiple Sclerosis or residual signs/symptoms from a previous stroke).
- Skin conditions which prevent assessment of the relevant areas affected by peripheral neuropathy.
- Suffering from significant psychiatric illness, which would hinder their completion of the study in the opinion of the investigator.
- General medical condition is unstable or rapidly deteriorating, such that they are unlikely to be able to contribute to the study.
- In the opinion of the Research Team or their usual medical team, would be unable to complete the study protocol for any other reason.
- Current treatment of ≤ 30 days duration with topical lidocaine patch/gel or anticonvulsants, tricyclic antidepressants, MAO inhibitor, or other neuropathic pain medication agents such as carbamazepine, phenytoin, valproic acid, gabapentin/pregabalin, lamotrigine or amifostine. (If on the same dose of any of these medications for >31 days, patients will be asked to continue these for the duration of the study. Analgesic agents such as acetaminophen, nonsteroidal anti-inflammatory agents, or opioids, are allowed if on the same doses for >31 days).
- Application of capsaicin cream or patch (to the limb extremities) currently or within the last 30 days (as this would interfere with application of the menthol gel and potentially study outcome).
- Patients with significant pain other than CIPN (ie pain worse than the CIPN).
- Other medical conditions, which in the opinion of the treating physician/allied health professional would make this protocol unreasonably hazardous for the patient.
- Participants previously randomised into this study.
- Participants not prepared to stop using any other physical activity meter.
- Co-enrolment in any other pain treatment studies.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Menthol
Menthol gel to be applied twice a day for 6 weeks - toes to knees, fingertips to elbows, top and base of spine.
|
Application of gel for 6 weeks.
|
Placebo Comparator: Placebo
Placebo gel to be applied twice a day for 6 weeks - toes to knees, fingertips to elbows, top and base of spine.
|
Application of gel for 6 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Reduction in CIPN symptoms
Time Frame: 6 weeks
|
A clinically significant reduction in pain (at least a 30% decrease in total BPI SF score as relates to the index neuropathic pain) between baseline and 6 weeks.
|
6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Treatment effect on Chemotherapy Induced Peripheral Neuropathy
Time Frame: 6 weeks
|
Changes in EORTC QLQ (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaires) CIPN-20 (severity of 20 symptoms rated on 4 point scale from Not at all to Very much)
|
6 weeks
|
Treatment effect on quality of life functions
Time Frame: 6 weeks
|
Changes in EORTC QLC-c30 scores (30 symptoms on same scale as CIPN)
|
6 weeks
|
Treatment effect on pain scores
Time Frame: 6 weeks
|
Changes in Brief Pain Inventory - Short Form scores (13 symptoms rated from 0 None to 10 Worst)
|
6 weeks
|
Treatment effect on anxiety and depression
Time Frame: 6 weeks (14 symptoms rated from 0 to 3 in severity)
|
Changes in Hospital Anxiety and Depression Scale (HADS) scores
|
6 weeks (14 symptoms rated from 0 to 3 in severity)
|
Treatment effect on pain catastrophisation
Time Frame: 6 weeks (13 questions rated from 0-4 in severity)
|
Changes in Pain Catastrophising Scale (PCS) scores
|
6 weeks (13 questions rated from 0-4 in severity)
|
Treatment effect on side effects
Time Frame: 6 weeks
|
Changes in side effects (Yes/No to any SEs, description of SE to be given)
|
6 weeks
|
Treatment effect on physical activity
Time Frame: 6 weeks
|
Changes in Actigraph data (measures of step counts, amount of moderate/vigorous activity and sleep times/efficiency)
|
6 weeks
|
Perceived effects of IMP
Time Frame: 6 weeks
|
Changes in perceived effects questions (How long participant thinks treatment takes to take effect and how long it lasts for)
|
6 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in Functional Magnetic Imaging data
Time Frame: 6 weeks
|
Changes in FMRI data pre and post treatment
|
6 weeks
|
Post treatment changes in CIPN
Time Frame: 12 weeks (from baseline)
|
Changes in CIPN-20 scores (see secondary outcomes above for details of all questionnaire measures)
|
12 weeks (from baseline)
|
Post treatment changes in quality of life measures
Time Frame: 12 weeks (from baseline)
|
Changes in QLQ-c30
|
12 weeks (from baseline)
|
Post treatment changes in pain scores
Time Frame: 12 weeks (from baseline)
|
Changes in BPI-SF
|
12 weeks (from baseline)
|
Post treatment changes in anxiety and depression
Time Frame: 12 weeks (from baseline)
|
Changes in HADS scores
|
12 weeks (from baseline)
|
Post treatment changes in pain catastrophising
Time Frame: 12 weeks (from baseline)
|
Changes in PCS
|
12 weeks (from baseline)
|
Post treatment changes in side effects
Time Frame: 12 weeks (from baseline)
|
Changes in Side effects
|
12 weeks (from baseline)
|
Post treatment changes in physical activity
Time Frame: 12 weeks (from baseline)
|
Changes in Actigraph data
|
12 weeks (from baseline)
|
Changes in sensory measures
Time Frame: 6 weeks and 12 weeks (from baseline)
|
Changes in QST data
|
6 weeks and 12 weeks (from baseline)
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MINT
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chemotherapy-induced Peripheral Neuropathy
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Leiden University Medical Center; Reinier de GraafRecruitingChemotherapy-induced Peripheral Neuropathy | CIPN - Chemotherapy-Induced Peripheral Neuropathy | Qutenza | DuloxetineNetherlands
-
Arash Asher, MDVoxxLifeRecruitingNeuropathy | Chemotherapy-induced Peripheral Neuropathy | Neuropathy;PeripheralUnited States
-
Institut Cancerologie de l'OuestGrünenthal GmbHNot yet recruitingChemotherapy-induced Peripheral Neuropathy
-
Odense University HospitalAarhus University Hospital; University of Southern Denmark; Sygehus LillebaeltRecruitingChemotherapy-induced Peripheral NeuropathyDenmark
-
WinSanTor, IncRecruitingChemotherapy-induced Peripheral NeuropathyUnited States
-
Veloxis PharmaceuticalsRecruitingChemotherapy-induced Peripheral NeuropathyUnited States, Japan
-
National University Hospital, SingaporePaxman Coolers Ltd.; The N.1 Institute for Health, National University of SingaporeRecruitingChemotherapy-induced Peripheral NeuropathySingapore
-
University of Rochester NCORP Research BaseNational Cancer Institute (NCI)RecruitingChemotherapy-Induced Peripheral NeuropathyUnited States
-
Donna Hammond, PhDActive, not recruitingChemotherapy-induced Peripheral NeuropathyUnited States
-
University of Rochester NCORP Research BaseNational Cancer Institute (NCI)CompletedEffects of Transcutaneous Electrical Nerve Stimulation on Chemotherapy-Induced Peripheral NeuropathyChemotherapy-Induced Peripheral NeuropathyUnited States
Clinical Trials on MINT study IMP
-
University of BolognaUnknown
-
PfizerEli Lilly and CompanyCompletedOsteoarthritisUnited States, Spain, Australia, Serbia, Germany, Canada, Japan, New Zealand, Hungary, Italy, Sweden, Lithuania, Portugal, Russian Federation, Slovakia
-
PfizerEli Lilly and CompanyCompletedOsteoarthritis | Cancer Pain | Recurrent Low Back PainUnited States
-
Sanoculis LtdCompletedThis Study is Obtained Under Inclusion/ Exclusion CriteriaArmenia
-
Postgraduate Institute of Dental Sciences RohtakUnknownPeriodontal Bone LossIndia
-
Air Force Military Medical University, ChinaCompleted
-
University of ValenciaMinisterio de Sanidad, Servicios Sociales e IgualdadRecruitingDrug Abuse | Alcohol Abuse | Intimate Partner Violence Against WomenSpain
-
AvenCell Europe GmbHPHARMALOG Institut für klinische Forschung GmbHRecruitingBlastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | Acute Myeloid Leukemia (AML)Germany